Trials / Completed
CompletedNCT00846911
AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs
AVANTI - Avelox® in Acute Exacerbations of Chronic Bronchitis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 2,672 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 35 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin tablets in daily life clinical practice. This includes data on the course of symptom relief, speed of return to normal daily life activities as well as records on adverse events. This study will be performed in accordance with international guidelines like EMEA (EMEA, EUDRALEX Volume 9A, Pharmacovigilance for Medicinal Products for Human Use) as well as local laws.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Moxifloxacin (Avelox, BAY12-8039) | Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2010-04-01
- Completion
- 2010-04-01
- First posted
- 2009-02-19
- Last updated
- 2012-07-09
Locations
8 sites across 8 countries: Albania, Bosnia and Herzegovina, Kazakhstan, Moldova, North Macedonia, Russia, Slovakia, Ukraine
Source: ClinicalTrials.gov record NCT00846911. Inclusion in this directory is not an endorsement.